pLEX307-ACE2-blast Citations (4)

Originally described in: Coronavirus host receptors and proteases
Chavez Lab Unpublished

---

Articles Citing pLEX307-ACE2-blast

Articles
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Liu H, Iketani S, Zask A, Khanizeman N, Bednarova E, Forouhar F, Fowler B, Hong SJ, Mohri H, Nair MS, Huang Y, Tay NES, Lee S, Karan C, Resnick SJ, Quinn C, Li W, Shion H, Xia X, Daniels JD, Bartolo-Cruz M, Farina M, Rajbhandari P, Jurtschenko C, Lauber MA, McDonald T, Stokes ME, Hurst BL, Rovis T, Chavez A, Ho DD, Stockwell BR. Nat Commun. 2022 Apr 7;13(1):1891. doi: 10.1038/s41467-022-29413-2. PubMed
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. Iketani S, Hong SJ, Sheng J, Bahari F, Culbertson B, Atanaki FF, Aditham AK, Kratz AF, Luck MI, Tian R, Goff SP, Montazeri H, Sabo Y, Ho DD, Chavez A. Cell Host Microbe. 2022 Oct 12;30(10):1354-1362.e6. doi: 10.1016/j.chom.2022.08.003. Epub 2022 Aug 11. PubMed
SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression. Arshad N, Laurent-Rolle M, Ahmed WS, Hsu JC, Mitchell SM, Pawlak J, Sengupta D, Biswas KH, Cresswell P. Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2208525120. doi: 10.1073/pnas.2208525120. Epub 2022 Dec 27. PubMed
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Duan Y, Zhou H, Liu X, Iketani S, Lin M, Zhang X, Bian Q, Wang H, Sun H, Hong SJ, Culbertson B, Mohri H, Luck MI, Zhu Y, Liu X, Lu Y, Yang X, Yang K, Sabo Y, Chavez A, Goff SP, Rao Z, Ho DD, Yang H. Nature. 2023 Oct;622(7982):376-382. doi: 10.1038/s41586-023-06609-0. Epub 2023 Sep 11. PubMed

If you have published an article using this material, please email us at to have your article added to this page.